



IASLC ((1)) 2020 World Conference on Lung Cancer Singapore PROGRAM AT A GLANCE VIRTUAL



Vienna (CET)	Day 1 January 28	Day 2 January 29			Day 3 January 30			Day 4 January 31		
		Antibody	Immunotherapy	Locoregional/Oligo	Immuno-Biology	Screening/ED	Nursing/AHP	Palliative Care	Risk Reduction and Tobacco Control	Staging
		Health Services	Diagnostic/Pulmonology and Targeted Therapies	Early Stage	Pathology	Mesothelioma	Patient Advocacy	Targeted Therapies	SCLC/NET	Tumor Biology
4:00 - 02:00	Joint IASLC-CAALC-CSCO Session*	PL02: Innovation to Bridge Lung Cancer Care Tomorrow			PS01: Presidential Symposium			PLO4: A Vision for Clinical Trials in 2020 and Beyond		
			Live Q&A			Live Q&A			Live Q&A	
2:15 - 03:15		ES01: Choosing Systemic Therapies After Chemoimmunotherapy in NSCLC	OA01: Established Drugs in Special Populations and New Drugs in Established Populations	OA02: Updates in Locally Advanced NSCLC	ES09: Biomarkers in Immunotherapy	ES10: Advances in Lung Cancer Screening Through Imaging and Data Analytics Live Q&A	ES11: Practice-Changing Initiatives	ES20: Evidence Base for Symptom Management	ES21: The "How To" of Modern Tobacco Control Live Q&A	MA09: Prognosis an Staging Live Q&A
			LIVE Q&A	LIVE Q&A			Live Q&A			
3:30 - 04:30	ISO2: Industry Symposium*	OA03: Promising Antibody-Drug Conjugate and Cytotoxic Therapy in NSCLC	ESO2: Pro-Con: Do We Need Biomarkers to Guide the Choice of Immunotherapy Treatment?	ESO3: Understanding and Treating Oligometastatic Diseases	OA07: Immuno-biology and Novel Immunotherapeutics from Bench to Bed	ES12: Public Health Issues in Lung Cancer Screening		ES22: Quality of Life	OA10: The Slow Pandemic – Tobacco Control in the Prevention of Lung Cancer	ES23: Beyond the TN
		Live Q&A		Live Q&A	Live Q&A			Live Q&A	Live Q&A	
4:45 - 05:45	ISO3: Industry Symposium*	MA01: Novel Systemic Treatment in NSCLC	OA04: New Data from Rare EGFR Alterations	ES04: Strategies to Increase Cure Rates in Stage III NSCLC: Optimising Checkpoint	ES14: Novel Immunotherapy Strategies in NSCLC	MA05: Lung Cancer Screening	OA08: Putting the Patient at the Center: Holistic Patient Care	MA10: Assessing and Managing Supportive Care Needs	ES24: Challenges in Tobacco Control	ES25: Unmet Need Issues of Current TNN
		Live Q&A	Live Q&A	Inhibitors and Beyond		Live Q&A	Live Q&A	Live Q&A		Live Q&A
5:00 - 07:00	ISO4: Industry Symposium*	ISO8: Industry Symposium*	ISO9: Industry Symposium*	IS10: Industry Symposium*	IS11: Industry Symposium*	IS12: Industry Symposium*		IS13: Satellite CPD Symposium by ACE Oncology**	IS14: Industry Symposium*	IS15: Industry Symposiu
7:15 - 08:15	ISO5: Industry Symposium*	ESO5: Value in Lung Cancer, from Screening to Treatment	MA02: Technological *Advances in Diagnostics, Imaging and Therapeutics for Lung Cancer	ES06: Perioperative Therapy for Early Stage NSCLC	ES15: Getting All NSCLCs Genotyped: How Can We Get to 100%?	MA06: Molecular Developments and Novel Treatments in Mesothelioma and Thymoma	ES16: Joint Global Lung Cancer Coalition/IASLC Session: Hot Topics for Advocates	MA11: Expanding Targetable Genetic Alterations in NSCLC	ES26: Future Horizons in the Management of Small Cell Lung Cancer	ES27: Heterogeneity Metastases and Resistance
		Live Q&A	Live Q&A			Live Q&A	Live Q&A	Live Q&A		Live Q&A
3:30 - 09:30	ISO6: Industry Symposium*	OA05: Value and Quality in Lung Cancer	ESO7: Pleural Effusion in a Cancer Patient	MA03: New and Revisited Factors in Early Stage Lung Cancer	ES17: The New WHO Classification of Lung Tumors	OA09: Mesothelioma from Pathogenesis to Therapy	for People with Lung Cancer: Decision Making, Survivorship, and New Challenges During	ES28: Targeting KRAS	OA11: A Symphony of Progress	ES29: Advances in Omics - Next Generation
		Live Q&A		Live Q&A	Live Q&A	Live Q&A	COVID-19		Live Q&A	Live Q&A
9:45 - 10:45	ISO7: Industry Symposium*	MAO4: Health Policy and the Real World	ESO8: The Solitary Pulmonary Nodule	OA06: Updates on EGFR Targeted Perioperative Therapy and Precision Adjuvant Chemotherapy	MAO8: Advances in Biomarkers for Immune Checkpoint Blockade and Targeted Therapy in Non-Small Cell Lung Carcinoma	ES18: The Future of Immunotherapy in Unresectable Mesothelioma	ES19: Patient-Reported Outcomes, Patient Registries and Real-World Evidence: Learning Directly from Patients	ES30: What is the Best Treatment Strategy to Target Rare Mutations	MA12: Controversies Old and New	MA13: Tumor Biology Focus on EGFR Mutati DNA Repair and Tum Microenvironment
			Live Q&A	Live Q&A	Live Q&A		Live Q&A	Live Q&A	Live Q&A	
:00 - 13:00	PL01: Opening Plenary	PL03: Bench to Bedside (Immunology)			PS02: Presidential Symposium (Rebroadcasted)			PLO5: Affordable and Accessible Lung Cancer Care		
	Session	Live Q&A			Live Q&A			Live Q&A		

*Not for CME Credit, see page 2 for more details for more information about the Industry Symposium sessions. **CME or CDP Accredited by Other Provider, see page 2 for more details.

IS - Industry Symposium, Satellite CME Symposium or Satellite CDP Symposium





IASLC ((1)) 2020 World Conference on Lung Cancer Singapore PROGRAM AT A GLANCE VIRTUAL



Vienna (CET)	Day 1 January 28	Day 2 January 29	Day 3 January 30	Day 4 January 31		
24:00 - 02:00						
02:15 - 03:15	ISO1: Satellite CME Symposium by Clinical Care Options: Advances in Antibody-Drug Conjugates for Treatment of Non-Small-Cell Lung Cancer					
03:30 - 04:30	ISO2: Industry Symposium Sponsored by AstraZeneca: Evolving the Role of Immunotherapy in Lung Cancer: ES-SCLC and Unresectable Stage III NSCLC					
04:45 - 05:45	ISO3: Industry Symposium Sponsored by Daiichi-Sankyo: Antibody Drug Conjugates (ADC) as Therapeutic Options for Advanced NSCLC: Opportunities and Challenges					
06:00 - 07:00	ISO4: Industry Symposium Sponsored by Eli Lilly: Implementing Precision Oncology in the Clinic: Diagnostic Challenges and Best Practices	ISO8: Industry Symposium Sponsored by Janssen: What the Future Holds for Advanced NSCLC Patients with Resistance to EGFR TKIs ISO9: Industry Symposium Sponsored by Pfizer: Expert Question Time: ALK+ NSCLC Bristol-Myers Squibb: Thoracic Cancers, New Developments with IO	IS11: Industry Symposium Sponsored by Amgen: Advancing the Next Frontier of Innovation in Lung Cancer Therapies IS12: Industry Symposium Sponsored by Boehringer Ingelheim: Know Your Patients With NSCLC	IS13: Satellite CPD Symposium Symposium Symposium Symposium by ACE Oncology: Hot Topics in the Management of Advanced Non-Small Cell Lung Cancer: Expert Insights on Recent Advances IS14: Industry Symposium Sponsored by AstraZeneca: Evolving Treatment and Testing Paradigms in EGFR-mutated NSCLC: The MDT Perspective Panel Testing		
07:15 - 08:15	ISO5: Industry Symposium Sponsored by MSD: Redefining Survival Expectations in Lung Cancer					
08:30 - 09:30	ISO6: Industry Symposium Sponsored by Novartis: Novel Frontiers in the Treatment of NSCLC					
09:45 - 10:45	IS07: Industry Symposium Sponsored by Roche: Expert Perspectives on the Management of Lung Cancer					
11:00 - 13:00						